Trial Profile

A Phase 1/2 Study of SL-401 as Consolidation Therapy for Adult Patients With Adverse Risk Acute Myeloid Leukemia in First CR, and/or Evidence of Minimal Residual Disease (MRD) in First CR

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 21 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Oct 2022 Results of an integrated analysis assessing aggregated safety data for Tagraxofusp monotherapy from three clinical trials: Study 0114, Study 0214 and Study 0314 published in the Clinical Lymphoma, Myeloma & Leukemia
13 Jan 2022 Status changed from completed to discontinued.
14 Dec 2021 Results from three phase 1/2 studies (Study 0114 (NCT02113982), Study 0214 (NCT02270463), and Study 0314 (NCT02268253) presented at the 63rd American Society of Hematology Annual Meeting and Exposition

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com